TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5

被引：0

|

作者：

Prada, M. ^{[1
]}

Berard, I ^{[2
]}

Walzer, S. ^{[3
]}

Darba, J. ^{[4
]}

Greenwood, B. ^{[5
]}

机构：

[1] Intexo, Rome, Italy

[2] NEXTEP, Paris, France

[3] MArS Market Access & Pricing Strategy GmbH, Weil Am Rhein, Germany

[4] Univ Barcelona, Barcelona, Spain

[5] Decideum, London W8 7JB, England

来源：

VALUE IN HEALTH | 2018年 / 21卷

关键词：

D O I：

10.1016/j.jval.2018.04.1761

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PSY119

引用

收藏

页码：S264 / S264

页数：1

相关论文

共 50 条

[31] A PRICE COMPARISON STUDY OF RECENT DRUGS IN EU5, 2008-2012
Le Pen, C.
Vigier, D.
Grandfils, N.
VALUE IN HEALTH, 2013, 16 (07) : A455 - A455
[32] TIME TRENDS IN SEQUENCE OF DRUG LAUNCH ACROSS EU5
Gubbels, L.
Dekkers, R.
Nijhuis, T.
VALUE IN HEALTH, 2016, 19 (07) : A451 - A451
[33] PRICE-DOSE RELATIONSHIP: THE CASE OF ORAL ONCOLOGY DRUGS IN EU5
Czira, A.
Pacheco, L.
Teale, C. W.
VALUE IN HEALTH, 2017, 20 (09) : A430 - A430
[34] Orphan drugs EU regulations
Mariz, Segundo
Llinares, Jordi
Westermark, Kerstin
BMJ-BRITISH MEDICAL JOURNAL, 2011, 342
[35] EU POLICY ON ORPHAN DRUGS
LEWIS, S
LANCET, 1995, 345 (8963): : 1500 - 1500
[36] AN ANALYSIS OF PRICE AND ACCESS TIMELINE OF ONCOLOGY DRUGS ACROSS EU5 COUNTRIES
Wang, X.
VALUE IN HEALTH, 2018, 21 : S22 - S22
[37] Orphan Drug Pricing and Reimbursement Policies Lacking in EU
不详
PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 297 - 298
[38] SINK OR SWIM: HOW CAN SLE BIOLOGICS SUCCESSFULLY ACHIEVE OPTIMAL REIMBURSEMENT AND UPTAKE IN THE EU5?
Privolnev, Y.
Albacker, C.
Nasa, M.
VALUE IN HEALTH, 2019, 22 : S51 - S52
[39] HOW CAN PHARMA INDUSTRY PREPARE ITSELF FOR THE CHANGING PRICING AND REIMBURSEMENT LANDSCAPE OF ORPHAN DRUGS IN EU?
Mukku, S.
Pang, F.
Mcconkey, D.
VALUE IN HEALTH, 2011, 14 (07) : A357 - A357
[40] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
Rinke van den Brink
Orphanet Journal of Rare Diseases, 9 (Suppl 1)

← 1 2 3 4 5 →